Adriane Bradberry

How I Do It: Pediatric Psoriasis Cases

Dr. Chiu presented information about the treatment of pediatric psoriasis beyond the use of topical steroids. First, Dr. Chiu described treatment options for pediatric psoriasis when topical steroids are insufficient. When discussing treatment options with the family, she typically offers three categories: phototherapy, oral medication, and injectables. Dr. Chiu reads the room and uses parents’…

Atopic Dermatitis: Guidelines of Care

Dr. Cohen presented information about the updated guidelines from the American Academy of Dermatology (AAD) for topical, systemic, and phototherapy treatments for atopic dermatitis (AD).   First, Dr. Cohen discussed updated AAD guidelines for topical therapies. Moisturizers, calcineurin inhibitors, topical corticosteroids, topical phosphodiesterase-4 (PDE-4) inhibitors, and Janus kinase (JAK) inhibitors are strongly recommended. Dr. Cohen encouraged…

Challenging Cases That Have Taught Me Oncology

Dr. Choi presented three oncodermatology cases that demonstrate clinical pearls for the diagnosis and treatment of oral graft versus host disease (GVHD), nutritional deficiencies, and aleukemic leukemia cutis (LC). Case #1 A 71-year-old female with acute lymphoblastic leukemia and hematopoietic stem cell transplant (HSCT) presented with oral pain and bleeding and bruising of the gums…

Varicose Veins for Dermatologists

Dr. Wysong presented information about varicose veins for dermatologists. Dermatologists frequently see patients with venous disease in clinic but have limited formal training in treating it. First, Dr. Wysong shared an overview of varicose vein disease including anatomy, epidemiology, pathophysiology, and clinical presentation. Venous insufficiency is the inability of the blood to return efficiently from…

Dr. Aimee Payne’s Path to Creating CAAR-T Cell Therapies

In 2011, Aimee Payne, MD, PhD, was running a lab at the University of Pennsylvania, studying pemphigus vulgaris, an autoimmune disease of the skin that results when B cells make antibodies that attack the cell-adhesion protein desmoglein 3.

Through the Lens of Education

Timothy T. Berger, MD, has always been a visual person and likes the stories art can tell. He understands something in the clinic better when he can draw a picture of it. Dr. Berger was Professor of Clinical Dermatology in the Department of Dermatology at the UCSF School of Medicine and, for his dedication to…

60 Years of Discovery and Counting

In the 1950s, Dr. Stephen Rothman was among those who pioneered the idea of investigative dermatology, believing physicians should apply basic scientific research to the practice of our specialty. Dermatologists embraced the role of science in dermatology, including those who created the Dermatology Foundation in 1964. They based the Foundation on a simple idea: that…

In Step With Patients and Residents

For more than 40 years, whether in a clinical setting or within university walls, Dr. Jeffrey Herten, the 2023 DF Clark W. Finnerud Award recipient, has been able to convey his love of the specialty and his compassion towards patients. He graduated from the Medical School of the University of California, Irvine, (UCI) in 1972…

Stuff I Worry About: High-Risk Squamous Cell Carcinoma and High-Risk Patients

Dr. Baum presented information about tumor- and patient-specific risk factors for cutaneous squamous cell carcinoma (cSCC). First, Dr. Baum noted that the cSCC incidence in the US is increasing, with an estimated 180,000–520,000 new cases annually and a metastatic rate of 2–5%. Patients with bulky nodal disease have higher recurrence rates and lower overall survival…

In-Transit Melanoma Metastases

Dr. Baum described melanoma in-transit metastases (ITMs) and presented an overview of current treatments. Melanoma ITMs are lesions that develop between the primary tumor site and the draining nodal basin via lymphatic seeding, separate from spreading in the blood. ITMs occur in 5–10% of patients with melanoma and typically develop within 13–18 months. Fifty percent…